Theravance Biopharma
TBPH
119 hedge funds and large institutions have $369M invested in Theravance Biopharma in 2024 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 43 reducing their positions, and 25 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 43
3.31% less ownership
Funds ownership: 96.86% → 93.55% (-3.3%)
8% less capital invested
Capital invested by funds: $399M → $369M (-$30.6M)
10% less funds holding
Funds holding: 132 → 119 (-13)
52% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 25
95% less call options, than puts
Call options by funds: $6K | Put options by funds: $110K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$20.6M |
| 2 |
MAP
Madison Avenue Partners
New York
|
+$8.66M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.28M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$1.41M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$35.6M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$1.68M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.41M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.38M |
| 5 |
HF
HRT Financial
New York
|
-$1.3M |
TBPH Hedge Fund Activity: Q3 2024 in Review
119 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2024, worth a combined $369M — down 7.7% from $399M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of TBPH and 12 opened new positions — a net loss of 13 holders — while 43 trimmed existing stakes and 40 added.
The largest buyer was Newtyn Management, adding an estimated $20.6M. The largest seller was Baupost Group, exiting entirely with an estimated $35.6M sold.
- 119 institutional investors held Theravance Biopharma (TBPH) as of Q3 2024, down from 132 in Q2 2024.
- Funds reported $369M of Theravance Biopharma stock for Q3 2024, down 7.7% quarter-over-quarter.
- 12 funds opened new Theravance Biopharma positions in Q3 2024 and 25 closed out, a net change of -13 holders.
- The largest Theravance Biopharma buyer in Q3 2024 was Newtyn Management, an estimated $20.6M added.
- The largest Theravance Biopharma seller in Q3 2024 was Baupost Group, an estimated $35.6M sold.
Based on aggregated 13F filings for Q3 2024.